Igc Pharma, Inc. · AMEX:IGC
Igc Pharma — Investor Presentation (December 2022)
25 slides from Igc Pharma's investor presentation, December 2022
Slide 1: Life Sciences Presentation
NYSE American LIFE SCIENCES PRESENTATION December 2022
Slide 2: Safe Harbor
Safe HARBOR The matters discussed in this presentation include forward-looking statements about the business prospects of India Globalization Capital, Inc. Forward-looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes or simil
Slide 3: Two Subsidiaries
Two Subsidiaries 1. IGC Pharma Two drug candidates focused on Alzheimer’s disease 2. HH Processors Focused on women’s wellness products and healthy energy seltzers 3 3
Slide 4: Why IGC? The Promise of IGC-AD1
WHY IGC? The Promise of IGC-AD1 We believe we are • The FIRST natural cannabis-based patent-protected compound that relies on low doses of THC, a psychoactive cannabinoid, and another compound as active agents for the treatment of Alzheimer’s disease • The ONLY natural THC-based investigational drug
Slide 5: Diverse Growth Opportunities
DIVERSE GROWTH OPPORTUNITIES Clear strategic focus Patent-protected investigational drug candidate IGC-AD1 in Phase 2 trial - the first human trial using low doses of natural THC to treat symptoms of dementia in Alzheimer’s. Patent-protected drug candidate TGR-63 is a plaque aggregation inhibitor sh
Slide 6: Vertically Integrated Operations
VERTICALLY INTEGRATED OPERATIONS . . 7
Slide 7: First Mover Advantage with Intellectual Property
FIRST MOVER ADVANTAGE WITH INTELLECTUAL PROPERTY PATENTS TARGET DESCRIPTION PATENT PENDING GRANTED Compositions and Methods for Treating CNS Alzheimer's Disease (IGC-AD1) 1 2 Disorders: CNS/Alzheimer Disease Alzheimer’s Disease (TGR-63) Self-Assembly of NMI Derivatives and its impact on Aβ protein
Slide 8: Two Lead Candidates Targeting Alzheimer's Disease
TWO LEAD CANDIDATES TARGETING ALZHEIMER’S DISEASE (AD) IGC-AD1 Treatment of Symptoms Our lead therapeutic candidate entering Phase 2 trials for treating agitation in dementia from Alzheimer’s Disease TGR-63 Treatment of Disease A plaque aggregation inhibitor shown in pre- clinical trials to reduce n
Slide 9: Alzheimer's Disease - A Critical Unmet Need
ALZHEIMER’S DISEASE - A CRITICAL UNMET NEED 6.5 Million 13.8 Million Americans with Americans with Alzheimer’s Disease in 2022 Alzheimer’s Disease by 2050 Fifth-Leading $1 Trillion Cause of death among Expected total expenses Americans Age 65+ for Alzheimer’s and other dementias by 2050 Alzheimer’s
Slide 10: IGC-AD1: A Promising Therapy for Alzheimer's
Researchers at the University of South Florida discovered the potential for cannabis to play a role in treating Alzheimer’s. The discovery was featured on Dr. Sanjay Gupta’s CNN show “Weed 2” In 2017, IGC acquired the exclusive rights to the research data and patent filing. Based on the research IGC
Slide 11: Phase 2 Trial Focus: Agitation in Alzheimer's
PHASE 2 TRIAL FOCUS: AGITATION IN ALZHEIMER’S 76% of Alzheimer’s patients suffer from agitation Emotional distress, verbal and physical aggression, irritability, and disinhibition Currently there are no FDA-approved medications to alleviate agitation in AD dementia Ingestion of medical cannabis is c
Slide 12: Our Promising IGC-AD1 Platform
OUR PROMISING IGC-AD1 PLATFORM Pre-clinical studies: decreased plaques and decreased pTau, two hallmarks of Alzheimer’s: • Inhibits the aggregation of amyloid plaque • Reduces phosphorylated tau (pTau) • Enhances mitochondrial function • Non-toxic. Repeated low dosing over 48 hours is non-toxic J. P
Slide 13: Memory Improved in AD (APP/PS1) Mouse Model
MEMORY IMPROVED IN AD (APP/PS1) MOUSE MODEL AD model mice dosed with the active agent in IGC-AD1 had significantly improved times and less errors in a Morris Water Maze test than those in the control group • The maze uses spatial cues for mice to navigate a swimming container full of stained water a
Slide 14: IGC-AD1 Phase 1 Trial Completed
IGC-AD1 PHASE 1 Safety, Tolerability, Agitation, NPS TRIAL COMPLETED No life-threatening or serious adverse Multiple Ascending Dose (MAD) study to events at any dosing level evaluate safety and tolerability of IGC-AD1 in participants with AD & NPS using the NPI (NPS: Neuropsychiatric Systems. NPI: N
Slide 15: IGC-AD1 Phase 2 Trial Has Commenced
IGC-AD1 PHASE 2 TRIAL HAS COMMENCED Placebo Controlled, Double Blind, Randomized, Multi Site Phase 2 protocol seeks to show that IGC’s low dose THC based investigational drug, IGC-AD1, is effective, compared to placebo, in lowering agitation in participants with Alzheimer’s Objective Evaluate if IGC
Slide 16: TGR-63 A Promising Path-Breaking Molecule
TGR-63 A PROMISING PATH- BREAKING MOLECULE IGC acquired exclusive rights to TGR-63 from researchers at India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) who created the TGR-63 molecule. Pre-clinical testing demonstrates that TGR-63 holds potential to ameliorate plaque–one
Slide 17: Sr. Scientific Trial Team
SR. SCIENTIFIC TRIAL TEAM Scientific Management Inventors Dr. Varduhi Ghazaryan, MD, MPH Prof. Chuanhai Cao, PhD Medical Director Professor of Pharmaceutical Science Dr. Saadia Shahnawaz, MD Medical Director Prof. T Govindaraju, PhD, FRSC. Dr. Juan Manuel Orjuela, MD Professor - Bioorganic Chemis
Slide 18: Potential to Drive Significant Growth
POTENTIAL TO DRIVE SIGNIFICANT GROWTH NORTH AMERICA AND EUROPE Individuals with AD 15M 15M 15M Agitation in AD 11M 11M 11M % adoption of drug (IGC-AD1) 3% 5% 10% Annual Price/Patient of drug $1,200 – $2,400 $1,200 – $2,400 $1,200 – $2,400 Estimated Revenue $0.4B – $0.8B $0.6B - $1.3B $1.3B - $2.6B K
Slide 19: OTC Products, GMP Facilities, Pharma Manufacturing
OTC Products GMP Facilities Pharma Manufacturing
Slide 20: Growing Family of Wellness Products
GROWING FAMILY OF WELLNESS PRODUCTS 21
Slide 21: Women's Health & Wellness Science
WOMEN’S HEALTH & Non-GMO, vegan line of over-the-counter “OTC” wellness WELLNESS SCIENCE products with natural ingredients designed for women by women PMS, period cramps, fitness, & sleep, Holief™ covers a spectrum of wellness through a line of products that meets the highest standards and values Fr
Slide 22: Energy Drinks Are Changing the Seltzer Game
Energy drinks are changing the seltzer game Low-calorie carbonated energy drink with natural caffeine from green tea extract, hemp (CBD), vitamin B and C, no added sugars and no preservatives Sunday Seltzer also offers seltzer in four flavors with hemp (CBD), vitamin B, vitamin C, and no caffeine 23
Slide 23: From Lab-to-Market: Sales Beginning to Ramp
FROM LAB-TO-MARKET Sales Beginning Unique End-to-end Capabilities To Ramp Our formulations Q2 ’23 ended 9/30/22 R&D: Ability to source and manufacture product at scale Brand creation, fulfillment & shipping E-commerce and data analytics Q2 ’22 ended Global customer engagement through 9/30/21 strateg
Slide 24: Summary
SUMMARY To our knowledge, IGC-AD1 is the ONLY natural low dose THC-based investigational drug candidate currently undergoing FDA trials in Alzheimer’s IGC-AD1 Phase 2 Trial has commenced, based on positive findings in Phase 1 Short- and long-term strategies to address Alzheimer’s Disease with signif
Slide 25: Thank You
THANK YOU (= IGC
India Globalization Capital, Inc. (IGC Pharma) — Investor Presentation (December 2022) on 6ix